AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Public Health, Vol. 71, Issue 2 138-144, Copyright © 1981 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, R E
Right arrow Articles by Specht, E E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, R E
Right arrow Articles by Specht, E E
The risk of hip fracture in postmenopausal females with or without estrogen drug exposure.

R E Johnson and E E Specht

This study estimated the risk of hip fracture among postmenopausal females with and without estrogen drug exposure. The Kaiser-Permanente Medical Care Program in Portland, Oregon served as the setting and medical records the source of data. A retrospective case-control method that matched each female member hospitalized with a hip fracture (N = 168) between 1965-1975 with two control female members hospitalized for reasons other than a hip fracture was used. The estrogen exposure rate of cases was 29.2 per cent and of controls 36.0 per cent. The risk of hip fracture was reduced with postmenopausal and prefracture estrogen exposure (RML = 0.72, 95 per cent CL: 0.48-1.09). However, the number of cases was sufficient only to detect a reduction in risk of about 50 per cent or greater. A possible protective effect from estrogens was also suggested with oral estrogen exposure and with longer lengths of estrogen exposure.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
R. Marcus, M. Wong, H. Heath III, and J. L. Stock
Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Endocr. Rev., February 1, 2002; 23(1): 16 - 37.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. M. Grossman and C. H. MacLean
Quality Indicators for the Management of Osteoporosis in Vulnerable Elders
Ann Intern Med, October 16, 2001; 135(8_Part_2): 722 - 730.
[Full Text] [PDF]


Home page
NEJMHome page
D. T. Felson, Y. Zhang, M. T. Hannan, D. P. Kiel, P. Wilson, and J. J. Anderson
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
N. Engl. J. Med., October 14, 1993; 329(16): 1141 - 1146.
[Abstract] [Full Text]


Home page
Journal of Applied GerontologyHome page
A.-L. Furstenberg and M. D. Mezey
Community Residence One Year After Hip Fracture
Journal of Applied Gerontology, June 1, 1988; 7(2): 193 - 204.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American Public Health Association